Do South African Xhosa-Speaking People with Schizophrenia Really Fare Better?
A Longitudinal Mortality Study in Older Patients with Schizophrenia
Abstract
Abstract.Objectives: Results from multinational WHO studies suggest that schizophrenia patients in developing countries may have more favorable prognoses and morbidity outcomes than those in developed settings. This study serves to establish whether mortality outcomes in South African Xhosa-speaking schizophrenia patients are more favorable than in the general South African population. Methods: We recruited a group of 981 patients from September 1997 to March 2005 as part of a genetic study in the Western, Southern, and Eastern Cape provinces of South Africa. For this substudy, participants were included when they reached the age of 60 years during the study period (8–15 years). We examined factors associated with the probability of dying and computed survival times using national census data as reference. Results: At the time of follow-up, 73 individuals were 60 years or older (21.9% could not be traced); some 40% of the sample had died at the time of the follow-up assessment (mean age at death = 60.12 years, SD = 4.97). Univariate survival analysis, using duration of disorder, revealed that the number of hospitalizations and psychotic episodes impacted survival time. Compared to the age-specific death rates of the general South African population, the death rate in the Xhosa-speaking schizophrenia sample was higher than expected in the 60–69 years category, but lower than expected in the 70+ years category. Conclusion: This study suggests that increased exposure to inpatient mental healthcare (expressed as number of hospitalizations) at baseline, and number of psychotic episodes, improve survival probability in a group of older South African Xhosa-speaking schizophrenia patients.
References
2006). Perceptions of a South African schizophrenia population regarding community attitudes towards their illness. Social Psychiatry & Psychiatric Epidemiology, 41, 619–623.
(2004). Occupation and schizophrenia in a Xhosa population: A variant of the social drift theory? South African Medical Journal, 94, 42.
(2009). Schizophrenia and the incidence of cardiovascular morbidity. Schizophrenia Research, 115, 325–332.
(2009). Does a diagnosis of schizophrenia reduce rates of mammography screening? A Manitoba population-based study. Schizophrenia Research, 113, 95–100.
(2013). The incidence and all-cause mortality of pneumonia in patients with schizophrenia: A nine-year follow-up study. Journal of Psychiatric Research, 47, 460–466.
(2011). The incidence and relative risk factors for developing cancer among patients with schizophrenia: A nine-year follow-up study. Schizophrenia Research, 129, 97–103.
(2019). HIV, schizophrenia, and all-cause mortality: A population-based cohort study of individuals accessing universal medical care from 1998 to 2012 in British Columbia, Canada. Comparative Outcomes and Service Utilization Trends (COAST) Study. Schizophrenia Research, 209, 198–205.
, et al. (2008). Questioning an axiom: Better prognosis for schizophrenia in the developing world? Schizophrenia Bulletin, 34, 229–244.
(2007). Appendectomy for appendicitis in patients with schizophrenia. The American Journal of Surgery, 193(1), 41–48.
(2006). Adverse events during medical and surgical hospitalizations for persons with schizophrenia. Archives of General Psychiatry, 63, 267–272.
(2019). The impact of a psychiatry clinical rotation on the attitude of South African final year medical students towards mental illness. BMC Medical Education, 19, 114.
(2014). Rapid mortality surveillance report 2013. Cape Town: South African Medical Research Council.
(2001). Quality of medical care and excess mortality in older patients with mental disorders. Archives of General Psychiatry, 58, 565–572.
(2002). Ethnicity and treatment response in schizophrenia: A comparison of 3 ethnic groups. Journal of Clinical Psychiatry, 63(1), 9–14.
(2014). Undiagnosed metabolic syndrome and other adverse effects among clozapine users of Xhosa descent. South African Journal of Psychiatry, 20(2), 54–57.
(2013). Schizophrenia and the risk of cardiovascular diseases: A meta-analysis of thirteen cohort studies. Journal of Psychiatric Research, 47, 1549–1556.
(2007). Quality of diabetes care among adults with serious mental illness. Psychiatric Services, 58, 536–543.
(2018). Social disconnection in schizophrenia and the general community. Schizophrenia Bulletin, 44, 242–249.
(2001). Recovery from psychotic illness: A 15- and 25-year international follow-up study. British Journal of Psychiatry, 178, 506–517.
(2017). Years of potential life lost and life expectancy in schizophrenia: A systematic review and meta-analysis. Lancet Psychiatry, 4, 295–301.
(2015). Course and outcome of schizophrenia in Asian countries: Review of research in the past three decades. Asian Journal of Psychiatry, 14, 3–12.
(2015). Loneliness and social isolation as risk factors for mortality: A meta-analytic review. Perspectives on Psychological Science, 10, 227–237.
(2003). Community attitudes toward and knowledge of mental illness in South Africa. Social Psychiatry and Psychiatric Epidemiology, 38, 715–719.
(2015). The mortality risk of conventional antipsychotics in elderly patients: A systematic review and meta-analysis of randomized placebo-controlled trials. Journal of the American Medical Directors Association, 16, 817–824.
(2008). What did the WHO studies really find? Schizophrenia Bulletin, 34, 253–255.
(2017). Unresolved issues for utilization of atypical antipsychotics in schizophrenia: Antipsychotic polypharmacy and metabolic syndrome. International Journal Molecular Sciences, 18(10), 601–612.
(2001). Mental disorders and cause specific mortality. British Journal of Psychiatry, 179, 498–502.
(2005). Mortality in individuals who have had psychiatric treatment: Population-based study in Nova Scotia. British Journal of Psychiatry, 187, 552–558.
(2007). Negative symptoms and HIV/AIDS risk behaviour knowledge in schizophrenia. Psychosomatics, 48, 128–134.
(1919). Dementia praecox and paraphrenia. Edinburgh: Livingstone.
(2012). High mortality and low access to care following incident acute myocardial infarction in individuals with schizophrenia. Schizophrenia Research, 142(1–3), 52–57.
(2018). A widening longevity gap between people with schizophrenia and general population: A literature review and call for action. Schizophrenia Research, 196, 9–13.
(2014). Attempted suicide in a Xhosa schizophrenia and schizoaffective disorder population. Suicide and Life-Threatening Behaviour, 44, 167–174.
(2015). Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatrica Scandinavica, 132, 97–108.
(2009). Are cervical cancer screening rates different for women with schizophrenia? A Manitoba population-based study. Schizophrenia Research, 113, 101–106.
. (2002). Attitudes towards and beliefs about schizophrenia in Xhosa families with affected probands. Curiatonis, 25(1), 69–73.
(2015). Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: A systematic analysis for the global burden of disease study 2013. Lancet, 385, 117–171.
. (2006). Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Research, 86, 15–22.
(1991). Mortality in a cohort of patients with schizophrenia: A record linkage study. Canadian Journal of Psychiatry, 36, 239–245.
(2004). Suicide attempts in an African schizophrenia population: An assessment of demographic risk factors. Suicide and Life-Threatening Behaviour, 34, 320–327.
(2005). Positive and negative symptoms in affected sibling pairs with schizophrenia: Implications for genetic studies in an African Xhosa sample. Schizophrenia Research, 15(79), 239–249.
(2013). Increasing mortality gap for patients diagnosed with schizophrenia over the last three decades: A Danish nationwide study from 1980 to 2010. Schizophrenia Research, 146(1–3), 22–27.
(2000). Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophrenia Research, 29(45), 21–28.
(2006). Is the outcome of schizophrenia really better in developing countries? Brazilian Journal of Psychiatry, 28, 149–152.
(2017). Causes of mortality in schizophrenia: An updated review of European studies. Psychiatria Danubina, 29, 108–120.
(2014). Increased mortality in schizophrenia because of cardiovascular disease: A non-systematic review of epidemiology, possible causes, and interventions. Frontiers of Psychiatry, 5, 137.
(2015). Divorce and health: Current trends and future directions. Psychosomatic Medicine, 77, 227–236.
(2015). Long-term clinical course and outcome of schizophrenia in rural Ethiopia: A 10-year follow-up of a population-based cohort. Schizophrenia Research, 161, 414–420.
(2012). Widowhood and mortality: A meta-analysis and meta-regression. Demography, 49, 575–606.
(2014). Mortality and causes of death in South Africa, 2011: Findings from death notification. Pretoria: Stats SA. Retrieved from http://www.statssa.gov.za/publications/P03093/P030932011.pdf
. (2017). Antipsychotic medication and long-term mortality risk in patients with schizophrenia: A systematic review and meta-analysis. Psychological Medicine, 47, 2217–2228.
(2011). Existential questions in schizophrenia: Perceptions of patients and caregivers. Revista Saúde Pública, 45, 401–408.
(2015). Mortality in mental disorders and global disease burden implications: A systematic review and meta-analysis. JAMA Psychiatry, 72, 334–341.
(2017). Cancer mortality in patients with schizophrenia: Systematic review and meta-analysis. British Journal of Psychiatry, 211(1), 7–13.
(